Walgreens and Freenome Announce Multi-year Partnership

Walgreens and Freenome have announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer. Walgreens will utilize its resources to engage diverse patient populations in Freenome’s multi-cancer research program.

Working together with technology provider Curebase, Walgreens will initially recruit patients across diverse populations for Freenome’s Sanderson Study, which aims to evaluate blood-based early detection tests for multiple cancers. Using Curebase’s platform, Walgreens will deliver targeted outreach to potentially eligible patients and caregivers of all backgrounds via text, email, or in-person consultation at the pharmacy. After completing a pre-screen, eligible patients are invited to enroll in the study. Walgreens healthcare providers will then perform a single blood draw at one of the company’s clinical trial locations and conduct a telehealth patient follow-up one year after their participation.

The Sanderson Study will enroll approximately 8,000 participants through its clinical study partner network, which includes Walgreens.

Walgreens and Freenome will also work together on building risk-prediction models and population health software. The aim is to help close existing care gaps and identify people who are eligible and stand to benefit from standard-of-care cancer detection testing. Real-world data collected by Walgreens as part of this collaboration will inform the development of new products and services in Freenome’s multi-cancer detection research, including the company’s blood-based colorectal cancer screening test.

Reference

Walgreens and Freenome Partner to Increase Diversity in Research Focused on the Early Detection of Cancer. (2023, June 15). Walgreens.